Expression, purification and crystallization of CTB-MPR, a candidate mucosal vaccine component against HIV-1

Ho‐Hsien Lee, Irene Cherni, Hongqi Yu, Raimund Fromme, Jeffrey D. Doran, Ingo Grotjohann, Michele Mittman, Shibom Basu, Arpan Deb, Katerina Dörner, Andrew Aquila, Anton Barty, Sébastien Boutet, Henry N. Chapman, R. Bruce Doak, Mark S. Hunter, Daniel James, Richard A. Kirian, Christopher Kupitz, Robert M. Lawrence, Haiguang Liu, Karol Nass, Ilme Schlichting, K. E. Schmidt, M. Seibert, Robert L. Shoeman, John C. H. Spence, Francesco Stellato, Uwe Weierstall, Garth J. Williams, Chunhong Yoon, Dingjie Wang, Nadia A. Zatsepin, Brenda G. Hogue, Nobuyuki Matoba, Petra Fromme, Tsafrir S. MorIUCrJ 2014 · DOI

TL;DR

This paper reports on the expression, purification, and crystallization of CTB-MPR, a fusion protein designed as a potential HIV-1 mucosal vaccine. By developing and testing different linker variants, the researchers aimed to obtain structural insights into this promising immunogen. While traditional crystallography yielded limited structural information, the application of femtosecond nanocrystallography to tiny crystals proved successful, demonstrating its utility for proteins that resist macroscopic crystal formation.

What Problem Does This Paper Address?

The development of an effective HIV-1 vaccine remains a significant challenge. One promising strategy involves targeting the virus at mucosal surfaces, where initial infection often occurs. The membrane-proximal region (MPR) of the HIV-1 gp41 envelope protein is a key target for broadly neutralizing antibodies and plays a crucial role in viral fusion and transmission. However, the MPR itself is a poor immunogen and is sensitive to its structural context. To overcome this, researchers fused the MPR to cholera toxin B subunit (CTB), a known mucosal targeting and immunogenic carrier. This CTB-MPR fusion protein has shown potential in inducing anti-HIV-1 antibodies. However, to further optimize this vaccine candidate, a deeper understanding of its structure is needed. This paper addresses the challenge of obtaining structural information for CTB-MPR, particularly for the MPR region, which is difficult to crystallize and may be conformationally flexible.

Methods

The researchers employed a multi-pronged approach involving protein engineering, expression, purification, and various crystallographic techniques:

  • Protein Engineering: Three variants of CTB-MPR were designed with different linker peptides between the CTB and MPR domains:
  • CTBGPGPMPR: Original construct with a flexible GPGP linker.
  • CTBMPR: Linker-less construct, directly fusing CTB to MPR.
  • CTBAAAAMPR: Construct with a short polyalanine (AAAA) linker, hypothesized to promote helical structure and stability.
  • Bacterial Expression and Purification: The fusion proteins were expressed in E. coli and purified using a combination of affinity chromatography (leveraging CTB's ability to bind metal-affinity resin without a His-tag) and size-exclusion chromatography (SEC-HPLC). Purification protocols were optimized to ensure homogeneity and compatibility with crystallization.
  • Traditional X-ray Crystallography: Initial attempts were made to crystallize the purified proteins using vapor-diffusion techniques. Diffraction data was collected from any crystals obtained.
  • Dynamic Light Scattering (DLS): Used to assess the size distribution and monodispersity of the purified proteins.
  • Serial Femtosecond Nanocrystallography (SFX): This cutting-edge technique was applied to tiny nano/microcrystals of CTBAAAAMPR. SFX uses extremely short, high-intensity X-ray pulses from a free-electron laser to collect diffraction data before the crystal is destroyed by radiation. This allows for data collection from very small crystals that would be impossible with traditional methods.

Datasets

Not explicitly discussed as "datasets" in the traditional machine learning sense. The primary "data" used for analysis were:

  • Purified CTB-MPR protein variants: These were generated and characterized in-house.
  • X-ray diffraction data: Collected from crystals of CTBGPGPMPR and CTBAAAAMPR (both macroscopic and nano/microcrystals).
  • Existing protein structures: Used for molecular replacement during crystallographic phasing (e.g., PDB entry 1jr0 for CTB).

Key Insights and Ideas

  • Linker Flexibility is Crucial: The nature of the linker between CTB and MPR significantly impacts protein stability and crystallization. The flexible GPGP linker in CTBGPGPMPR allowed for CTB pentamer formation but prevented the MPR from being resolved structurally. The linker-less CTBMPR showed instability and dynamic oligomeric states, hindering crystallization. The polyalanine linker in CTBAAAAMPR provided better stability and homogeneity.
  • Femtosecond Nanocrystallography is a Game-Changer: For proteins that resist forming macroscopic crystals, SFX offers a powerful alternative. The ability to collect diffraction data from nano/microcrystals of CTBAAAAMPR, which were ordered in three dimensions unlike their larger counterparts, highlights the potential of this technique for structural biology.
  • CTB Pentamer Stability: The CTB subunit consistently formed stable pentamers across different variants, even when fused to the MPR. This inherent stability of CTB was leveraged for purification.
  • MPR Conformation Remains Elusive: Despite efforts, the precise structure of the MPR region in the fusion protein remained challenging to resolve, suggesting its inherent flexibility or dynamic nature in the pre-fusion state.

Key Results

  • CTBGPGPMPR: Yielded crystals diffracting to 2.3 Å, but only the CTB portion was structurally resolved.
  • CTBMPR: Showed dynamic oligomeric states and failed to form ordered crystals.
  • CTBAAAAMPR: Was more stable and homogeneous than CTBMPR, but macroscopic crystals were poorly ordered. However, nano/microcrystals of CTBAAAAMPR diffracted to 5 Å resolution using SFX, demonstrating their three-dimensional order.
  • SFX Data: Diffraction patterns from CTBAAAAMPR nano/microcrystals indicated a hexagonal crystal system (space group R32) with unit-cell parameters suggesting potential similarity to viral protein structures.

Limitations and Future Work

  • MPR Structure: The full structure of the MPR region within the CTB-MPR fusion protein could not be resolved using traditional crystallography, suggesting it may be inherently flexible or adopt multiple conformations in the pre-fusion state.
  • Macroscopic Crystal Disorder: While nano/microcrystals of CTBAAAAMPR showed order, larger crystals grown under similar conditions were disordered in the third dimension.
  • Future Work:
    • Structure Determination: Further SFX experiments with higher data redundancy are needed to determine the structure of CTBAAAAMPR.
  • Co-crystallization: Co-crystallization with neutralizing antibodies is suggested to gain insights into antibody-antigen interactions.
  • NMR and other techniques: Exploring other structural methods for the MPR region is implied.
  • Optimizing Nano/Microcrystal Growth: Developing methods to grow defined micrometre-sized crystals from the nano/microcrystals for conventional X-ray data collection is a key future direction.
  • Vaccine Optimization: The ultimate goal is to use structural information to design an optimal CTB-MPR construct for a vaccine.

Summary updated

Abstract

CTB-MPR is a fusion protein between the B subunit of cholera toxin (CTB) and the membrane-proximal region of gp41 (MPR), the transmembrane envelope protein of Human immunodeficiency virus 1 (HIV-1), and has previously been shown to induce the production of anti-HIV-1 antibodies with antiviral functions. To further improve the design of this candidate vaccine, X-ray crystallography experiments were performed to obtain structural information about this fusion protein. Several variants of CTB-MPR were designed, constructed and recombinantly expressed in Escherichia coli. The first variant contained a flexible GPGP linker between CTB and MPR, and yielded crystals that diffracted to a resolution of 2.3 Å, but only the CTB region was detected in the electron-density map. A second variant, in which the CTB was directly attached to MPR, was shown to destabilize pentamer formation. A third construct containing a polyalanine linker between CTB and MPR proved to stabilize the pentameric form of the protein during purification. The purification procedure was shown to produce a homogeneously pure and monodisperse sample for crystallization. Initial crystallization experiments led to pseudo-crystals which were ordered in only two dimensions and were disordered in the third dimension. Nanocrystals obtained using the same precipitant showed promising X-ray diffraction to 5 Å resolution in femtosecond nanocrystallography experiments at the Linac Coherent Light Source at the SLAC National Accelerator Laboratory. The results demonstrate the utility of femtosecond X-ray crystallography to enable structural analysis based on nano/microcrystals of a protein for which no macroscopic crystals ordered in three dimensions have been observed before.
BibTeX
@inproceedings{lee2014expression,
  author = {Ho‐Hsien Lee and Irene Cherni and Hongqi Yu and Raimund Fromme and Jeffrey D. Doran and Ingo Grotjohann and Michele Mittman and Shibom Basu and Arpan Deb and Katerina Dörner and Andrew Aquila and Anton Barty and Sébastien Boutet and Henry N. Chapman and R. Bruce Doak and Mark S. Hunter and Daniel James and Richard A. Kirian and Christopher Kupitz and Robert M. Lawrence and Haiguang Liu and Karol Nass and Ilme Schlichting and K. E. Schmidt and M. Seibert and Robert L. Shoeman and John C. H. Spence and Francesco Stellato and Uwe Weierstall and Garth J. Williams and Chunhong Yoon and Dingjie Wang and Nadia A. Zatsepin and Brenda G. Hogue and Nobuyuki Matoba and Petra Fromme and Tsafrir S. Mor},
  title = {{Expression, purification and crystallization of CTB-MPR, a candidate mucosal vaccine component against HIV-1}},
  booktitle = {IUCrJ},
  year = {2014},
  doi = {10.1107/s2052252514014900},
}
Figure